MHP
AEGR

Manatuck Hill Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Manatuck Hill Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-51,400
Closed -$4.41M – 118
2013
Q3 		$4.41M Sell
51,400
-196,000
-79% -$16.6M 0.57% 47
2013
Q2 		$15.7M Buy
+247,400
New +$13.1M 1.91% 18

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manatuck Hill Partners's AEGR Position: Q4 2013 in Review

Manatuck Hill Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 51,400 shares — an estimated $4.41M sold.

Manatuck Hill Partners first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $15.7M in Q2 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Manatuck Hill Partners reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Manatuck Hill Partners sold 51,400 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $4.41M.
  • Manatuck Hill Partners first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Manatuck Hill Partners's Aegerion Pharmaceuticals position peaked at $15.7M in Q2 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Manatuck Hill Partners's 13F filing for Q4 2013, filed 14 Feb 2014.